Results 211 to 220 of about 10,900 (261)

The Impact of Palivizumab for Respiratory Syncytial Virus Prophylaxis on Preschool Childhood Asthma

Vaccines
Background: The respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and is associated with an increased risk of asthma development.
Hanna Hasson, Yoav Bachar, Itai Hazan, Inbal Golan-Tripto, A. Goldbart, D. Greenberg, Guy Hazan   +6 more
semanticscholar   +1 more source

[Recommendations on the use of palivizumab: update 2023].

Archivos Argentinos de Pediatria
The current document is an update of the recommendations of the Sociedad Argentina de Pediatría based on a bibliographic review of publication from recent years on the use of the monoclonal antibody against respiratory syncytial virus (RSV), palivizumab,
María J Fattore, Alejandro Maccarrone, Mariana Brusadin, María S Arbio, Gladys Saá   +4 more
semanticscholar   +1 more source

Comments on Palivizumab (Synagis)

Pediatrics, 1999
Caregivers and third-party payors need additional information from the Impact study1investigators to determine the appropriate use of palivizumab (Synagis) in select premature infants with increased risk of respiratory syncytial virus (RSV)-associated hospitalization.
F W, Moler, R W, Brown, R G, Faix, J R, Gilsdorf   +3 more
openaire   +2 more sources

Palivizumab: A debate about funding

Journal of Paediatrics and Child Health, 2010
AbstractA clinician and the chair of the hospital drug committee debate the merits of the use of palivizumab as prophylaxis against respiratory syncytial virus infection for a preterm baby with oxygen‐dependent, chronic lung disease and discuss the issue of public funding of palivizumab.
Fitzgerald, Dominic, Isaacs, David, Tobin, Bernadette   +2 more
openaire   +3 more sources

Improving the prescribing of palivizumab

Journal of Paediatrics and Child Health, 2018
AimPalivizumab prevents respiratory syncytial virus (RSV) in children at high risk of severe disease. This paper reviews the use and effectiveness of palivizumab at two tertiary paediatric hospitals (hospitals A and B) in New South Wales, Australia.MethodsChildren prescribed palivizumab during the pre‐intervention period, 1 January 2013 until 31 ...
Simone Trist, Emily Horsley, Hala Katf, Natalie Tasker, Mona Mostaghim   +4 more
openaire   +2 more sources

Palivizumab: an overview

Hospital Medicine, 1999
Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if ...
openaire   +2 more sources

Utilization and efficacy of palivizumab for children with Down syndrome

Pediatrics International, 2020
Palivizumab is a prophylactic drug used for severe respiratory syncytial virus (RSV) infection in young children with high‐risk factors, such as prematurity and congenital heart diseases.
Takeshi Kimura, Masato Takeuchi, K. Kawakami   +2 more
semanticscholar   +1 more source

Optimum Dosage Regimen of Palivizumab?

Therapeutic Drug Monitoring, 2002
Palivizumab is a humanized, monoclonal antibody used to protect at-risk infants against respiratory syncytial virus (RSV) infection. The regular dosage scheme causes a low initial trough level and accumulation of the antibody after subsequent injections.
Zaaijer, Hans L., Vandenbroucke-Grauls, C. M. J. E., Franssen, E. J. F.   +2 more
openaire   +3 more sources

Palivizumab prophylaxis in ‘late preterm’ newborns

The Journal of Maternal-Fetal & Neonatal Medicine, 2010
In the last decades the preterm birth rate rose more than 20%, largely because of an increase among deliveries of 'late preterm' infants, i.e. those born at 34 to 36 weeks gestational age. Late preterm infants are more susceptible to infection by pathogens, such as respiratory syncytial virus (RSV), possibly because of the immaturity of both the ...
LANARI, MARCELLO, Silvestri, Michela, Rossi, Giovanni A.   +2 more
openaire   +3 more sources

Cost–effectiveness of palivizumab in infancy

Expert Review of Pharmacoeconomics & Outcomes Research, 2007
Respiratory syncytial virus is the most common cause of bronchiolitis, a lower respiratory tract infection occurring in infancy. It is responsible for several rehospitalizations, substantial morbidity and occasional deaths in the UK every year. Palivizumab is a recombinant monoclonal antibody that has been shown to reduce hospitalizations in infected ...
Nicholas D, Embleton, Sandeep T, Dharmaraj, Sanjeev, Deshpande   +2 more
openaire   +2 more sources